Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Pharmagreen Biotech Inc PHBI

Pharmagreen Biotech, Inc. is a Canada-based company. The Company is engaged in developing its line of nutraceutical products, which is a blend of therapeutic plants and mushrooms. Utilizing the Company's expertise in plant genetics, its transgenic program uses the technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a... see more

OTCPK:PHBI - Post Discussion

Pharmagreen Biotech Inc > Pharmagreen is in the right place at the right time.
View:
Post by ElliotGH on Dec 20, 2022 9:27am

Pharmagreen is in the right place at the right time.

The Global Nutraceuticals Market is excepted to reach the value of 722.49 billion USD by the end of 2027. $PHBI, Pharmagreen is in the right place at the right time.
 
https://www.einnews.com/pr_news/602403405/the-global-nutraceuticals-market-is-excepted-to-reach-the-value-of-722-49-billion-usd-by-the-end-of-2027
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities